OS2.3 Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma <GBM> patients <PTS>

BACKGROUND: There is no established treatment regimen for recurrent GBM. GBMs have activation of multiple signaling pathways in the tumor microenvironment, including the receptor tyrosine kinases, VEGFR, FGFR, and PDGFR. Regorafenib (REG), an oral multikinase inhibitor, inhibits these angiogenic kin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Lombardi, G, de Salvo, G, Rudà, R, Franceschi, E, Eoli, M, Faedi, M, Pace, A, Lolli, I, Rizzato, S, Germano, D, Pasqualetti, F, Farina, M, Magni, G, Bellu, L, Caccese, M, Pambuku, A, Bergo, E, Indraccolo, S, Gardiman, M, Soffietti, R, Zagonel, V
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Oral Presentations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144013/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.016
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars